Deutsche Bank AG Cuts Position in HilleVax, Inc. $HLVX

Deutsche Bank AG lessened its holdings in HilleVax, Inc. (NASDAQ:HLVX) by 22.8% during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 324,484 shares of the company’s stock after selling 96,066 shares during the period. Deutsche Bank AG owned approximately 0.65% of HilleVax worth $471,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of HLVX. Millennium Management LLC raised its holdings in HilleVax by 59.6% during the 4th quarter. Millennium Management LLC now owns 411,820 shares of the company’s stock valued at $852,000 after acquiring an additional 153,815 shares during the period. Two Sigma Advisers LP lifted its stake in HilleVax by 76.8% during the fourth quarter. Two Sigma Advisers LP now owns 41,200 shares of the company’s stock worth $85,000 after purchasing an additional 17,900 shares during the last quarter. Federated Hermes Inc. lifted its stake in HilleVax by 128.3% during the first quarter. Federated Hermes Inc. now owns 24,429 shares of the company’s stock worth $35,000 after purchasing an additional 13,728 shares during the last quarter. Barclays PLC grew its stake in shares of HilleVax by 14.1% during the fourth quarter. Barclays PLC now owns 47,946 shares of the company’s stock valued at $100,000 after buying an additional 5,913 shares during the last quarter. Finally, Northern Trust Corp grew its stake in shares of HilleVax by 2.8% during the fourth quarter. Northern Trust Corp now owns 249,610 shares of the company’s stock valued at $517,000 after buying an additional 6,916 shares during the last quarter. Hedge funds and other institutional investors own 86.42% of the company’s stock.

HilleVax Stock Performance

HLVX opened at $2.08 on Thursday. HilleVax, Inc. has a fifty-two week low of $1.34 and a fifty-two week high of $2.17. The firm’s fifty day moving average is $2.06 and its 200 day moving average is $1.88. The stock has a market cap of $104.29 million, a price-to-earnings ratio of -1.45 and a beta of 0.77.

HilleVax (NASDAQ:HLVX) last released its earnings results on Wednesday, August 6th. The company reported ($0.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.03. On average, equities research analysts predict that HilleVax, Inc. will post -2.64 earnings per share for the current year.

Analysts Set New Price Targets

Separately, Zacks Research upgraded shares of HilleVax to a “hold” rating in a report on Friday, August 8th. Two investment analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, HilleVax has a consensus rating of “Hold” and a consensus price target of $2.00.

HilleVax Company Profile

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.